Document Detail

Lacosamide: in partial-onset seizures.
MedLine Citation:
PMID:  19323588     Owner:  NLM     Status:  MEDLINE    
Lacosamide is a functionalized amino acid, the antiepileptic effects of which appear to be due to a novel mode of action, namely the selective enhancement of slow inactivation of voltage-gated sodium channels. Lacosamide is available as oral or intravenous formulations. Bioequivalence between the oral tablet and the oral syrup of lacosamide has been established. The bioavailability of the oral lacosamide tablet was similar to that of a 30- or 60-minute intravenous infusion of lacosamide administered at the same dosage. Oral lacosamide when added concomitantly with between one and three antiepileptic drugs was effective in adult patients with uncontrolled partial-onset seizures with or without secondary generalization, according to pooled data (n = 1308) from three phase II/III studies that had a 12-week maintenance phase. The percentage of patients with a >or=50% reduction from baseline to the maintenance phase in seizure frequency was significantly greater with oral lacosamide 200 or 400 mg/day (34% and 40%) than with placebo (23%). The median percentage reduction in seizure frequency per 28 days from baseline to the maintenance phase was significantly greater with lacosamide 400 mg/day than with placebo in each of the three phase II/III studies. Lacosamide was generally well tolerated in adult patients with partial-onset seizures, with most treatment-emergent adverse events being of mild or moderate severity. Dizziness was the most common treatment-related adverse event. When used as short-term replacement for oral lacosamide, intravenous lacosamide was well tolerated when administered as a 15-, 30- or 60-minute infusion.
Sarah A Cross; Monique P Curran
Related Documents :
237498 - A primate model for testing anticonvulsant drugs.
21881918 - Phase i and pharmacokinetic study of dasatinib and cetuximab in patients with advanced ...
8764818 - Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy...
2304098 - Isoniazid toxicity presenting as seizures and metabolic acidosis.
8466018 - Dose-response effect of intrathecal alfentanil on canine lower urinary tract dynamics.
1784598 - Apparent enhancement by sch 23390 of apomorphine-induced locomotor activity in mice.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  69     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2009  
Date Detail:
Created Date:  2009-03-27     Completed Date:  2009-06-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  449-59     Citation Subset:  IM    
Wolters Kluwer Health | Adis, North Shore, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetamides / pharmacology,  therapeutic use*
Anticonvulsants / pharmacology,  therapeutic use*
Biological Availability
Drug Therapy, Combination
Epilepsies, Partial / drug therapy*
Seizures / drug therapy*
Therapeutic Equivalency
Reg. No./Substance:
0/Acetamides; 0/Anticonvulsants; 0/lacosamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intravenous proton pump inhibitors: an evidence-based review of their use in gastrointestinal disord...
Next Document:  Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia.